

Cite this: *RSC Adv.*, 2019, 9, 30768

# A multicomponent, facile and catalyst-free microwave-assisted protocol for the synthesis of pyrazolo-[3,4-*b*]-quinolines under green conditions†

Mandlenkosi Robert Khumalo, Surya Narayana Maddila, Suresh Maddila and Sreekantha B. Jonnalagadda \*

A facile, swift and ecofriendly microwave-assisted multi-component/one-pot protocol is designed for the synthesis of novel pyrazolo-[3,4-*b*]-quinolines at ambient temperature in aqueous ethanol as a reaction medium. The 18 novel pyrazolo-[3,4-*b*]-quinoline derivatives were synthesized by fusion of chosen aryl aldehyde, dimedone and 5-amino-3-methyl-1-phenylpyrazole in excellent yields (91–98%). All the molecular structures were confirmed by <sup>1</sup>H-NMR, <sup>15</sup>N-NMR, <sup>13</sup>C-NMR, and HRMS data analysis. Operational simplicity, easy handling, one-step simple workup procedure, mild reaction conditions, short reaction time (≤10 min), high selectivity and no by-product formation are the striking features of the protocol.

Received 19th June 2019  
Accepted 22nd September 2019

DOI: 10.1039/c9ra04604f

rsc.li/rsc-advances

## Introduction

The advent of green alternate multicomponent reactions (MCRs) has provided latitude for researchers to explore new reactions, which can create vital pharmaceutical and biological skeletons in an eco-friendly way.<sup>1,2</sup> In such reactions, multiple-bonds are formed between three or more reactants in a single step, with no need to isolate any intermediate or change the solvent.<sup>3</sup> MCRs are well-known tools for easy carbon-carbon bond creation in synthetic chemistry,<sup>4</sup> and offer an easy workup procedure, higher selectivity and improved yields due to generation of C-C and C-heteroatom bonds in a single step.<sup>2–4</sup> MCRs offer notable benefits including simple handling, construction of highly complex molecules in a single step, formation of products in higher yields and minimizing the need for purification.<sup>5,6</sup> Furthermore, atom economy, less solvent consumption and reduced waste generation are other key advantages.<sup>7–15</sup>

Microwave (MW) irradiation as a tool in organic synthesis has become important in the development of heterocyclic molecules and drug discovery processes, due to its ability to deliver improved yields in short reaction times.<sup>16,17</sup> MW irradiation enhances the reaction rates and facilitates the reaction in mild conditions.<sup>18</sup> The reaction rates get faster *via* a development of oscillation excitation, and mass

transference in a microwave-environment.<sup>19</sup> Further, MW irradiation displays many advantages like minimal energy consumption, minimal waste production and atom economy.<sup>20,21</sup> As MW irradiation directly couples the molecules in the reaction mixture, the choice of the solvent is crucial to achieve optimum reaction conditions.<sup>22</sup> Both polar (protic and aprotic) solvent are known to be effective in MW organic synthesis. Unlike non-polar solvents, such solvents can couple with a MW irradiation, thus generating more heat. Thus, MW irradiation provides a facile and benign means for synthesis of novel organic moieties, using one-pot approach.

Pyrazolo-[3,4-*b*]-quinolines are one of the most significant biological skeletons with wider applications in pharmaceutical and medicinal fields and in heterocyclic synthesis as intermediates.<sup>23,24</sup> These moieties are fused bioactive molecules with antimicrobial,<sup>25</sup> translocator protein ligands,<sup>26</sup> anticancer,<sup>27</sup> pulmonary hypertension,<sup>28</sup> cytotoxicity,<sup>29</sup> antiplatelet,<sup>30</sup> anti-chagasic,<sup>31</sup> antimalarial,<sup>32</sup> antiviral<sup>33</sup> and anti-inflammatory<sup>34</sup> activities. Additionally, these molecules have extensively explored as Alzheimer's disease<sup>35</sup> and anti-influenza virus<sup>36</sup> treatment agents. Due to their growing importance, several articles have been reported in the recent past, for the preparation of pyrazolo-[3,4-*b*]-quinoline scaffolds using different homogeneous and heterogeneous materials such as FeNi<sub>3</sub>-ILs,<sup>37</sup> PEG-OSO<sub>3</sub>H,<sup>38</sup> L-proline,<sup>39</sup> InCl<sub>3</sub> (ref. 40) and PEG-400 (ref. 41) as catalysts, to name few. However, the aforementioned procedures have limitations and they suffer from drawbacks, like prolonged reaction times, harsh reaction

School of Chemistry & Physics, University of KwaZulu-Natal, Westville Campus, Chiltern Hills, Durban, 4000, South Africa. E-mail: jonnalagaddas@ukzn.ac.za; Fax: +27 31 2603091; Tel: +27 31 2607325

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra04604f



conditions, catalyst separation challenges, tedious workup, waste generation, toxic solvents, high reaction temperatures and low product yields. Therefore, there is demand for newer methods that could surmount the above challenges. Here, we report an efficient catalyst-free one-pot protocol for the preparation of pyrazolo-[3,4-*b*]-quinolines under MW irradiation in aqueous EtOH at room temperature, reacting the chosen aryl aldehyde, dimedone and 5-amino-3-methyl-1-phenylpyrazole. There have been no earlier reports for the preparation of novel pyrazolo-[3,4-*b*]-quinoline derivatives under MWI.

## Experimental procedure

### General process for preparation of pyrazolo-[3,4-*b*]-quinoline derivatives


A mixture of aromatic aldehyde (1.0 mmol), dimedone (1.0 mmol) and 5-amino-3-methyl-1-phenylpyrazole (1.0 mmol) were placed in a microwave vessel containing 5.0 mL EtOH : H<sub>2</sub>O (1 : 1 v/v) solvent (Scheme 1). The reaction vessel was MW assisted by using microwave irradiation power (at 150 W) for 5 minutes at 50 °C. The reaction progress was checked by thin layer chromatography (TLC) analysis (eluent *n*-hexane: ethyl acetate 3 : 2 v/v). After completion of reaction, the reaction mixture, washed with cold water to afford the crude product. Then it was purified by recrystallization from ethanol to obtain target molecules. Structures of all products were confirmed based on the spectra analysis, <sup>1</sup>H-NMR, <sup>15</sup>N-NMR, <sup>13</sup>C-NMR and HRMS data. The instrumental details and spectral characterization data is incorporated in the ESI (SI-1†).

## Results and discussion

The pilot reaction was investigated using aromatic aldehyde (1 mmol), dimedone (1 mmol) and 5-amino-3-methyl-1-phenylpyrazole (1 mmol) under microwave irradiation and conventional stirring conditions to optimize the reaction conditions for the preparation of pyrazolo-[3,4-*b*]-quinoline derivatives. First, the reaction accomplishment was assessed by engaging a series of solvents (polar and/or non-

polar) as well as under solvent-free conditions to explore the target yields in shorter reaction times. Initially, the model reaction was conducted in the absence of any catalyst or solvent at room temperature (R.T). However, the reaction failed to give any product even after 6 h, under conventional or MWI conditions. Under both the conditions, no desired product detected, when the reaction was studied with non-polar solvents (hexane, toluene and DCM) for 6 h. In polar aprotic solvents (DMF, DMSO and THF), only a trace amount of yield was obtained with both the methods. Under polar protic solvents (H<sub>2</sub>O, MeOH and EtOH), only moderate yields occurred under silent method, even after 2 h, while good yields were noticed under MWI within 1 h. When, the reaction was carried in mixed solvent system (EtOH : H<sub>2</sub>O, 1 : 1 v/v), excellent yield (98%) was afforded in very short reaction time (5 min) under MWI (Table 1). As the mixture of polar solvents with higher dielectric constants could couple well with the microwave irradiation, it generates rapid heating.<sup>2,17</sup> Accepting an equal molar aqueous ethanol as ideal solvent for the reaction, the influence of catalyst on the product yield and reduce reaction time was further examined. The reaction with various catalysts like NaHCO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, pyridine, and trimethylamine (inorganic or organic) in aqueous ethanol system afforded moderate to good yields, under both the conditions. When the title reaction was investigated with 1-proline, an ionic liquid catalyst, both under silent and MWI conditions, no significant improvement was observed on the yield or reaction time. Hence, the reaction was optimized using benign and cost-effective aqueous ethanol as reaction medium as opposed to the other solvents and catalysts, under catalyst-free conditions.

Further, the effect of reaction temperature on the product yield in aqueous EtOH was investigated under MW and catalyst-free conditions. When the temperature was decreased from 50 to 30 °C, the yield reduced from 98 to 50%, and interestingly the increase in temperature from 50 °C to 100 °C, also registered decrease in yield (from 98 to 93%), with marginal change in reaction time. Therefore, the reaction in aqueous EtOH *via* MW irradiation at 50 °C proved optimum condition in terms of the yield and reaction time (Table 2).



Scheme 1 Three-component green synthetic route for pyrazolo-[3,4-*b*]-quinoline derivatives.



Table 1 Optimization of the model reaction under varied MW irradiation and silent conditions<sup>a</sup>

Entry	Catalyst	Condition	Conventional		MWI	
			Time (h)	Yield (%)	Time (h)	Yield <sup>b</sup> (%)
1	Catalyst free	R.T	6.0	— <sup>c</sup>	6.0	— <sup>c</sup>
2	Solvent free	R.T	6.0	— <sup>c</sup>	6.0	— <sup>c</sup>
3	Hexane	R.T	6.0	— <sup>c</sup>	6.0	— <sup>c</sup>
4	Toluene	R.T	6.0	— <sup>c</sup>	6.0	— <sup>c</sup>
5	DCM	R.T	6.0	— <sup>c</sup>	6.0	— <sup>c</sup>
6	DMF	R.T	6.0	Trace	6.0	Trace
7	DMSO	R.T	6.0	Trace	6.0	Trace
8	THF	R.T	6.0	Trace	6.0	Trace
9	H <sub>2</sub> O	R.T	2.0	71	1.0	83
10	MeOH	R.T	2.0	64	1.0	72
11	EtOH	R.T	2.0	74	1.0	90
12	EtOH : H <sub>2</sub> O	R.T	1.5	88	0.1	98
13	NaHCO <sub>3</sub>	R.T	1.5	56	0.5	89
14	K <sub>2</sub> CO <sub>3</sub>	R.T	1.0	61	0.5	90
15	Pyridine	R.T	1.5	51	0.75	84
16	TEA	R.T	1.0	49	0.75	81
17	L-proline	R.T	1.5	54	0.50	59

<sup>a</sup> All products were characterized by <sup>1</sup>H-NMR, <sup>15</sup>N NMR, <sup>13</sup>C-NMR and HRMS spectral analysis. <sup>b</sup> Isolated yields. <sup>c</sup> — no reaction.

Using the ideal reaction conditions, the strength of this protocol was assessed for the preparation of pyrazolo-[3,4-*b*]-quinoline derivatives from varied aldehydes. The catalyst-free MW procedure proved good for one-pot synthesis of eleven pyrazolo-[3,4-*b*]-quinoline derivatives offering excellent yields in all the reactions. All the substrates, containing both electron-donating and electron-withdrawing groups (irrespective of *ortho*, *meta* and *para* positions) on the phenyl ring, participated in the reaction giving excellent yields (Table 3). Aliphatic aldehydes such as propionaldehyde, butyraldehyde, phenylacetaldehyde and cyclohexanecarboxaldehyde failed to provide product yields under the chosen reaction conditions. All the compounds were characterized and confirmed by <sup>1</sup>H-NMR, <sup>15</sup>N-NMR, <sup>13</sup>C-NMR and HRMS.

A plausible mechanism for the synthetic reaction is illustrated in Scheme 2. It is proposed that initially, Knoevenagel condensation reaction occurs between an aryl

Table 3 Synthesis of pyrazolo-[3,4-*b*]-quinoline derivatives in ethanol under MW irradiation<sup>a</sup>

Entry	R	Product	Yield* (%)	Mp (°C)
1	2,3-OH	<b>4a</b>	94	119–121
2	2-CF <sub>3</sub>	<b>4b</b>	93	136–137
3	2-F	<b>4c</b>	94	183–184
4	2-Me	<b>4d</b>	98	200–201
5	3,4,5-OMe	<b>4</b>	94	197–198
6	3-OH, 4-OMe	<b>4f</b>	92	239–241
7	3-OMe	<b>4g</b>	96	176–178
8	4-Et	<b>4h</b>	95	246–248
9	4-OMe	<b>4i</b>	94	221–223
10	Benzaldehyde	<b>4j</b>	91	190–192
11	3-Pyridine	<b>4k</b>	94	239–241
12	3,4-OH	<b>4l</b>	95	216–217
13	3-F	<b>4m</b>	93	204–205
14	4-F	<b>4n</b>	94	221–223
15	4-Br	<b>4o</b>	92	190–192
16	4-Cl	<b>4p</b>	96	175–176
17	3,4-OMe	<b>4q</b>	96	235–237
18	2-Thio	<b>4r</b>	94	218–219

<sup>a</sup> Reaction conditions: arylaldehyde (1 mmol) dimedone (1 mmol) and 5-amino-3-methyl-1-phenylpyrazole one (1 mmol) in ethanol solvent (5 mL) were stirred at room temperature. R = substituted benzaldehydes, \* = isolated yields.


Table 2 Optimization of the temperature conversion of the model reaction<sup>a</sup>

Entry	Temperature (°C)	Time (min)	Yield (%)
1	30	60	50
2	40	30	71
3	50	5	98
4	60	5	98
5	70	5	97
6	80	5	96
7	90	5	95
8	100	5	93

<sup>a</sup> Reaction conditions: aromatic aldehyde one equivalent, dimedone one equivalent and 5-amino-3-methyl-1-phenylpyrazole one equivalent in EtOH : H<sub>2</sub>O aqueous solvent.

aldehyde (2) and dimedone (1), resulting in the adduct **A**, which is dehydrated to give intermediate **B**. Michael type addition reaction follows between 5-amino-3-methyl-1-phenylpyrazole (3) and intermediate **B**. The resulting intermediate, **C** rearranges to a stable adduct **D**, which is further cyclized and dehydrated to yield the product (4).





Scheme 2 Plausible reaction mechanism for the formation of pyrazolo-[3,4-*b*]-quinoline derivatives.

## Conclusion

In conclusion, we report a facile, convenient and green method for synthesis of eleven novel pyrazolo-[3,4-*b*]-quinolines under catalyst-free and aqueous solvent conditions *via* MW irradiation. The significant features of this present protocol being operational simplicity, simple workup procedure, mild conditions, short reaction times, high yields with high purity, and no column chromatography used for compound purification. To the best of our knowledge, this is the first report where MW irradiated has been used for the synthesis of pyrazolo-[3,4-*b*]-quinoline derivatives under catalyst-free and aqueous EtOH solvent condition. The present method will offer an attractive synthetic protocol for the preparation of structurally varied drug-like compounds for the pharmaceutical and drug design discovery fields.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Authors sincerely thank the School of Chemistry and Physics for the material support and facilities to conduct this work.

## References

- 1 S. Maddila, K. K. Gangu, S. N. Maddila and S. B. Jonnalagadda, *Curr. Org. Synth.*, 2017, **14**, 634.
- 2 S. N. Maddila, S. Maddila, M. Khumalo, S. V. H. S. Bhaskaruni and B. J. Sreekantha, *J. Mol. Struct.*, 2019, **1185**, 357–360.
- 3 S. V. H. S. Bhaskaruni, K. K. Gangu, S. Maddila and S. B. Jonnalagadda, *Chem. Rec.*, 2018, **18**, 1–21.
- 4 S. Maddila, K. K. Gangu, S. N. Maddila and S. B. Jonnalagadda, *Mol. Diversity*, 2017, **21**, 247–255.
- 5 S. Shabalala, S. Maddila, W. Van Zyl and S. B. Jonnalagadda, *Ind. Eng. Chem. Res.*, 2017, **56**, 11372–11379.
- 6 K. K. Gangu, S. Maddila and S. B. Jonnalagadda, *Ind. Eng. Chem. Res.*, 2017, **56**, 2917–2924.
- 7 C. Ma, J.-Y. Zhou, Y.-Z. Zhang, Y. Jiao, G.-J. Mei and F. Shi, *Chem. - Asian J.*, 2018, **13**, 2549–2558.
- 8 X.-X. Sun, C. Li, Y.-Y. He, Z.-Q. Zhu, G.-J. Mei and F. Shi, *Adv. Synth. Catal.*, 2017, **359**, 2660–2670.
- 9 Y.-M. Wang, H.-H. Zhang, C. Li, T. Fan and F. Shi, *Chem. Commun.*, 2016, **52**, 1804–1807.
- 10 X.-X. Sun, H.-H. Zhang, G.-H. Y.-Y. He and F. Shi, *Chem. - Eur. J.*, 2016, **22**, 17526–17532.
- 11 Q.-N. Zhu, Y.-C. Zhang, M.-M. Xu, X.-X. Sun, X. Yang and F. Shi, *J. Org. Chem.*, 2016, **81**, 7898–7907.
- 12 W. Dai, X.-L. Jiang, J.-Y. Tao and F. Shi, *J. Org. Chem.*, 2016, **81**, 185–192.



- 13 L. Wang, H.-H. Zhang, C. Li, T. Fan and F. Shi, *J. Org. Chem.*, 2017, **82**, 3605–3611.
- 14 W.-J. Hao, Q. Gao, B. Jiang, F. Liu, S.-L. Wang, S.-J. Tu and G. Li, *J. Org. Chem.*, 2016, **81**, 11276–11281.
- 15 T.-S. Zhang, Y.-J. Xiong, W.-J. Hao, X.-T. Zhu, S.-L. Wang, G. Li, S.-J. Tu and B. Jiang, *J. Org. Chem.*, 2016, **81**, 9350–9355.
- 16 H. Cho, F. Torok and B. Torok, *Green Chem.*, 2014, **16**, 3623–3634.
- 17 P. Cristian, V. Chiroasca, C. S. Heidenga and J. D. Hoeschele, *Dalton Trans.*, 2015, **44**, 3384–3392.
- 18 A. Kokel, C. Schafer and B. Torok, *Green Chem.*, 2017, **19**, 3729–3751.
- 19 A. Kulkarni and B. Torok, *Green Chem.*, 2010, **12**, 875–878.
- 20 P. Prasanna, K. Balamurugan, S. Perumal and J. C. Menendez, *Green Chem.*, 2011, **13**, 2123–2129.
- 21 A. Sharma, P. Appukkuttan and E. Van Eycken, *Chem. Commun.*, 2012, **48**, 1623–1637.
- 22 A. Dastan, A. Kulkarni and B. Torok, *Green Chem.*, 2012, **14**, 17–37.
- 23 V. Sharma, P. Bhatia, O. Alam, M. J. Naim, F. Nawaz, A. A. Sheikh and M. Jha, *Bioorg. Chem.*, 2019, **89**, 103007.
- 24 D. Raffa, B. Maggio, M. V. Raimondi, S. Cascioferro, F. Plescia, G. Cancemi and G. Daidone, *Eur. J. Med. Chem.*, 2015, **97**, 732–746.
- 25 S. T. Selvi, V. Nadaraj, S. Mohan, R. Sasi and M. Hema, *Bioorg. Med. Chem.*, 2006, **14**, 3896–3903.
- 26 A. Cappelli, G. Bini, S. Valenti, G. Giuliani, M. Paolino, M. Anzini, S. Vomero, G. Giorgi, A. Giordani, L. P. Stasi, F. Makovec, C. Ghelardini, L. Mannelli, A. Concas, P. Porcu and G. Biggio, *J. Med. Chem.*, 2011, **54**(20), 7165–7175.
- 27 C. Karthikeyan, R. Malla, C. R. Ashby, H. Amawi, K. L. Abbott, J. Moore, J. Chen, C. Balch, C. Lee, P. C. Flannery, P. Trivedi, J. S. Faridi, S. R. Pondugula and A. K. Tiwari, *Cancer Lett.*, 2016, **376**, 118–126.
- 28 L. Li, W. Zhang, F. Lin, X. Lu, W. Chen, X. Li, X. Zhou, R. Su, L. Wang, Z. Zheng and S. Li, *Eur. J. Med. Chem.*, 2019, **173**, 107–116.
- 29 C. Kurumurthy, B. Veeraswamy, P. S. Rao, G. S. Kumar, P. S. Rao, V. L. Reddy, J. Venkateswara Rao and B. Narsaiah, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 746–749.
- 30 A. L. Lourenco, R. R. S. Salvador, L. A. Silva, M. S. Saito, J. F. R. Mello, L. M. Cabral, C. R. Rodrigues, M. A. F. Vera, A. M. T. de Souza, C. S. Craik, L. R. S. Dias, H. C. Castro and P. C. Sathler, *Eur. J. Med. Chem.*, 2017, **135**, 213–229.
- 31 L. R. S. Dias, M. B. Santos, S. de Albuquerque, H. C. Castro, A. M. T. de Souza, A. C. C. Freitas, M. A. V. DiVaio, L. M. Cabral and C. R. Rodrigues, *Bioorg. Med. Chem. Lett.*, 2007, 211–219.
- 32 A. M. Hussin, F. A. Abu-Shanab and E. A. Ishak, *Elements*, 2000, **159**, 55–68.
- 33 A. R. Azevedo, V. F. Ferreira, H. de Mello, L. R. Leao-Ferreira, A. V. Jabor, I. C. P. P. Frugulhetti, H. S. Pereira, N. Moussatche and A. M. R. Bernardino, *Heterocycl. Commun.*, 2000, **8**, 427–432.
- 34 L. W. Mohamed, M. A. Shaaban, A. F. Zaher and S. M. A. and A. M. Elsahar, *Bioorg. Chem.*, 2019, **83**, 47–54.
- 35 T. Umar, S. Shalini, Md K. Raza, S. Gusain, J. Kumar, P. Seth, M. Tiwari and N. Hoda, *Eur. J. Med. Chem.*, 2019, **175**, 2–19.
- 36 Z. LY, T. Liu, J. Yang, Y. Yang, C. Cai and S. Liu, *ACS Comb. Sci.*, 2017, **19**(7), 437–446.
- 37 J. Safaei-Ghomi, R. Sadeghzadeh and H. Shahbazi-Alavi, *RSC Adv.*, 2016, **6**, 33676–33685.
- 38 S. Paul and A. R. Das, *Tetrahedron Lett.*, 2013, **54**, 1149–1154.
- 39 D. Bhattacharjee, B. Kshiar and B. Myrboh, *RSC Adv.*, 2016, **6**, 95944–95950.
- 40 J. M. Khurana, A. Chaudhary, B. Nand and A. Lumb, *Tetrahedron Lett.*, 2012, **53**, 3018–3022.
- 41 K. Karnakar, S. N. Murthy, K. Ramesh, G. Satish, J. B. Nanubolu and Y. Nageswar, *Tetrahedron Lett.*, 2012, **53**, 2897–2903.

